


Average Number of Months from Global First Launch to Public Insurance Reimbursement



■ Average Number of Months from Global First Launch to Country Approval

■ Average Number of Months from Country Approval to Public Insurance Reimbursement

*Medicare in the U.S.

Source: PhRMA analysis of IQVIA MIDAS®, GlobalData Drug Pricing Intelligence, and country government data on regulatory approval, pricing and reimbursement decisions, April 2026.
 Note: New medicines refers to all global new active substances first launched globally within the past 10 years (January 1, 2016 to December 31, 2025) and approved by the U.S. Food and Drug Administration, European Medicines Agency and/or Japan's Pharmaceuticals and Medical Devices Agency.
 A medicine is considered publicly reimbursed in Canada if 50% or more of the population lives in a province where it is publicly reimbursed. In most countries, patient access barriers remain when public reimbursement of medicines is restricted to only some of the approved indications and uses.